Editorial: Stem cells and progenitor cells in ischemic stroke—fashion or future? by Thorsten R. Doeppner & Dirk M. Hermann
EDITORIAL
published: 25 August 2015
doi: 10.3389/fncel.2015.00334
Frontiers in Cellular Neuroscience | www.frontiersin.org 1 August 2015 | Volume 9 | Article 334
Edited and reviewed by:
Egidio D’Angelo,
University of Pavia, Italy
*Correspondence:
Thorsten R. Doeppner,
thorsten.doeppner@uk-essen.de;
Dirk M. Hermann,
dirk.hermann@uk-essen.de
Received: 14 July 2015
Accepted: 10 August 2015
Published: 25 August 2015
Citation:
Doeppner TR and Hermann DM
(2015) Editorial: Stem cells and
progenitor cells in ischemic
stroke—fashion or future?
Front. Cell. Neurosci. 9:334.
doi: 10.3389/fncel.2015.00334
Editorial: Stem cells and progenitor
cells in ischemic stroke—fashion or
future?
Thorsten R. Doeppner * and Dirk M. Hermann*
Department of Neurology, University of Duisburg-Essen Medical School, Essen, Germany
Keywords: stem cells, cell transplantation, stroke, cerebral ischemia, neurogenesis, neuroregeneration
Despite recent achievements in re-canalizing stroke therapies (Campbell et al., 2015; Goyal
et al., 2015), which ensure reduction of deficits in a significant patient faction due to combined
systemic thrombolysis and interventional clot removal, a major need remains for restorative
therapies in patients suffering from persistent neurological deficits despite optimized treatment.
Although neurogenesis persists in the adult mammalian brain within distinct niches, such as
the subventricular zone (SVZ) hosting stem cells and neural progenitor cells (NPCs) alike,
the restorative potential of endogenous neurogenesis is generally insufficient and thus unable
to support a full recovery of lost functions following stroke. Consequently, transplantation of
exogenous NPCs and various other stem cell sources has emerged as a potential stroke treatment.
Although adult NPCs are not integrated into residing neural networks, solid experimental data
demonstrates beneficial effects in pre-clinical stroke models (Bacigaluppi et al., 2009; Doeppner
et al., 2012). Thorough insights into stem cell actions have been obtained in experimental studies
in recent years, which raise the questions about the clinical potential of stem cell-based therapies.
Themechanisms underlying post-stroke neurogenesis are diverse and highly complex, involving
interactions of stem cells with extracellular matrix (ECM) constituents, microvascular cells, brain
parenchymal cells, and immune cells, as summarized within this research topic by Hermann
et al. (2014). The pivotal role of calpains, which are activated upon post-ischemic cellular calcium
influx and control ECM remodeling, in post-stroke neurogenesis was now further analyzed by
Machado et al. (2015) who provide compelling evidence that deletion of the endogenous calpain
inhibitor calpastatin hampers the proliferation and migration of NPCs, whereas calpain inhibition
increases NPC proliferation, migration speed, andmigration distance. Accordingly, themodulation
of calpains might be a potent tool to boost post-stroke neurogenesis. Representing a molecular
substrate of calpains, themultifunctional ECMglycoprotein tenascin-C exemplifies in a particularly
multi-faceted way how the characteristics of stem cells are modified by ECM constituents upon
brain injury, as outlined by Roll and Faissner (2014). Casting new light onto the role of the
cerebral microvasculature for post-stroke neurogenesis, Adamczak et al. (2014) provide a detailed
non-invasive analysis of the dynamics of VEGF and its receptor VEGFR2 in a mouse model of
focal cerebral ischemia. The authors describe active VEGFR2 signaling for as long as 2 weeks
post-stroke that is likely to promote NPC migration and proliferation. Non-invasive imaging will
greatly facilitate research on neurogenesis in the near future, as stressed by Aswendt et al. (2014),
who systematically reviewed the requirements, advantages, and limitations of optical imaging as
compared with existing imaging techniques.
In light of the insufficient neurorestorative capacity of endogenous neurogenesis, various studies
aimed to support neurogenesis by cell transplantation. Due to their low immunogenicity and
easy accessibility, mesenchymal stem cells (MSCs) were by far most often used in experimental
stroke studies followed by NPCs. Yet, recovery-promoting actions can be achieved by various
cell sources, as shown in the present research topic for amniotic fluid-derived stem cells, which
protect the brain against ischemic injury (Tajiri et al., 2014). Yet, several open questions and
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pitfalls still have to be overcome to enable the translation of
stem cell therapy from bench to bedside. These include the
differentiation, fate and safety of transplanted cells as well as the
contamination of grafted cells with feeder cells that could also
pose a significant hazard to the recipient, as described by Ikegame
et al. (2014) and Molcanyi et al. (2014). As neither endogenous
nor exogenous adult stem cells are integrated into residing neural
networks, it stands to reason whether or not transplantation
of stem cells is mandatory for induction of neuroprotection.
Indeed, recent evidence suggests that extracellular vesicles
(e.g., exosomes) containing non-coding RNAs might be the
biologically activemediator of stem cell-induced neuroprotection
and brain plasticity (Xin et al., 2014). Extracellular vesicles might
allow for evading cell-based safety issues. This concept deserves
further in-depth evaluation in experimental systems and might
offer itself for subsequent proof-of-concept studies in human
stroke patients.
The vast majority of pre-clinical stroke studies were
hitherto limited to adolescent, otherwise healthy rodents, which
poorly reflects the clinical situation of elderly, multimorbid
stroke patients. In order to analyze consequences of arterial
hypertension, a particularly prevalent stroke risk factor, for
responses to stem cell therapy, Diederich et al. (2014) evaluated
effects of granulocyte-colony stimulating factor (G-CSF) and
bone marrow derived mononuclear cells (BM-MNCs) in
spontaneously hypertensive rats exposed to stroke (Diederich
et al., 2014). In their study, the combined delivery of G-
CSF and BM-MNCs was not superior to G-CSF alone. Most
importantly, single treatment with BM-MNCs did not yield any
therapeutic effect, in line with earlier data from this group
(Minnerup et al., 2014). The evaluation of risk factors, such
as arterial hypertension, will require intensified research in the
future. Beside co-morbidities, age-related changes of the cerebral
microenvironment have a strong impact on post-stroke brain
remodeling according to Popa-Wagner et al. (2014) who claim
that the aged brain is not refractory to post-stroke plasticity
after cell grafting. Yet, significant age-related changes have
been identified, i.e., a higher vulnerability to ischemic insults,
a reduced rate of neurogenesis, and a delayed initiation of
neurological recovery, which should carefully be considered
in the implementation of clinical proof-of-concept studies.
In view of age-related specificities, the neonatal mammalian
brain might provide a particularly suitable environment for cell
transplantation studies according to van Velthoven et al. (2014).
In the context of cell therapy, the selection of behavioral
tests has repeatedly been criticized. Thus, it was objected that
behavioral test batteries are optimized to detect functional
neurological improvements, the significance of which under
clinical conditions remains obscure. In a systematic study
including as many as 12 motor-coordination and cognitive tests,
Doeppner et al. (2014) now refute these criticisms, demonstrating
consistent improvement of neurological function in response
to NPC delivery across a large variety of tests. These data
provide strong evidence regarding the potency of stem cells
in experimental stroke settings, supporting the contributors’
overall view that cell-based therapies have true potential for
clinical translation. In light of a plethora of pre-clinical studies
demonstrating successful post-stroke neurological recovery and
brain remodeling after stem cell transplantation, first clinical
trials have already been performed on small patient cohorts,
as summarized by Doeppner and Hermann (2014). Promising
data were obtained particularly following intravenous MSC
delivery that until now, however, lack appropriate control groups.
Stringent proof-of-concept strategies including clear-defined
goals, measures, and actions will now have to be implemented,
which further bridge the gap between the laboratory bench and
the clinical setting. With such information, controlled clinical
proof-of-concept studies may then be scheduled providing
ultimate proofs whether cell-based therapies are able to enhance
neurological recovery post-stroke.
References
Adamczak, J. M., Schneider, G., Nelles, M., Que, I., Suidgeest, E., van der Weerd,
L., et al. (2014). In vivo bioluminescence imaging of vascular remodeling after
stroke. Front. Cell. Neurosci. 8:274. doi: 10.3389/fncel.2014.00274
Aswendt, M., Adamczak, J., and Tennstaedt, A. (2014). A review of novel optical
imaging strategies of the stroke pathology and stem cell therapy in stroke. Front.
Cell. Neurosci. 8:226. doi: 10.3389/fncel.2014.00226
Bacigaluppi, M., Pluchino, S., Peruzzotti-Jametti, L., Kilic, E., Kilic, U., Salani,
G., et al. (2009). Delayed post-ischaemic neuroprotection following systemic
neural stem cell transplantation involves multiple mechanisms. Brain 132(Pt
8), 2239–2251. doi: 10.1093/brain/awp174
Campbell, B. C., Mitchell, P. J., Kleinig, T. J., Dewey, H. M., Churilov, L., Yassi, N.,
et al. (2015). Endovascular Therapy for ischemic stroke with perfusion-imaging
selection. N. Engl. J. Med. 372, 1009–1018. doi: 10.1056/NEJMoa1414792
Diederich, K., Schmidt, A., Beuker, C., Strecker, J. K., Wagner, D. C., Boltze,
J., et al. (2014). Granulocyte colony-stimulating factor (G-CSF) treatment in
combination with transplantation of bone marrow cells is not superior to G-
CSF treatment alone after cortical stroke in spontaneously hypertensive rats.
Front. Cell. Neurosci. 8:411. doi: 10.3389/fncel.2014.00411
Doeppner, T. R., Ewert, T. A., Tönges, L., Herz, J., Zechariah, A., ElAli, A., et al.
(2012). Transduction of neural precursor cells with TAT-heat shock protein 70
chaperone: therapeutic potential against ischemic stroke after intrastriatal and
systemic transplantation. Stem Cells 30, 1297–1310. doi: 10.1002/stem.1098
Doeppner, T. R., and Hermann, D. M. (2014). Stem cell-based treatments
against stroke: observations from human proof-of-concept studies and
considerations regarding clinical applicability. Front. Cell. Neurosci. 8:357. doi:
10.3389/fncel.2014.00357
Doeppner, T. R., Kaltwasser, B., Bähr, M., and Hermann, D. M. (2014). Effects
of neural progenitor cells on post-stroke neurological impairment-a detailed
and comprehensive analysis of behavioral tests. Front. Cell. Neurosci. 8:338. doi:
10.3389/fncel.2014.00338
Goyal, M., Demchuk, A. M., Menon, B. K., Eesa, M., Rempel, J. L., Thornton,
J., et al. (2015). Randomized assessment of rapid endovascular treatment
of ischemic stroke. N. Engl. J. Med. 372, 1019–1030. doi: 10.1056/NEJMoa
1414905
Hermann, D. M., Peruzzotti-Jametti, L., Schlechter, J., Bernstock, J. D., Doeppner,
T. R., and Pluchino, S. (2014). Neural precursor cells in the ischemic brain -
integration, cellular crosstalk, and consequences for stroke recovery. Front. Cell.
Neurosci. 8:291. doi: 10.3389/fncel.2014.00291
Ikegame, Y., Yamashita, K., Nakashima, S., Nomura, Y., Yonezawa, S., Asano, Y.,
et al. (2014). Fate of graft cells: what should be clarified for development of
mesenchymal stem cell therapy for ischemic stroke? Front. Cell. Neurosci. 8:322.
doi: 10.3389/fncel.2014.00322
Frontiers in Cellular Neuroscience | www.frontiersin.org 2 August 2015 | Volume 9 | Article 334
Doeppner and Hermann Stem and progenitor cells in stroke
Machado, V. M., Morte, M. I., Carreira, B. P., Azevedo, M. M., Takano, J., Iwata,
N., et al. (2015). Involvement of calpains in adult neurogenesis: implications for
stroke. Front. Cell. Neurosci. 9:22. doi: 10.3389/fncel.2015.00022
Minnerup, J., Wagner, D. C., Strecker, J. K., Pösel, C., Sevimli-Abdis, S., Schmidt,
A., et al. (2014). Bone marrow-derived mononuclear cells do not exert acute
neuroprotection after stroke in spontaneously hypertensive rats. Front. Cell.
Neurosci. 7:288. doi: 10.3389/fncel.2013.00288
Molcanyi, M., Mehrjardi, N. Z., Schäfer, U., Haj-Yasein, N. N., Brockmann, M.,
Penner, M., et al. (2014). Impurity of stem cell graft by murine embryonic
fibroblasts - implications for cell-based therapy of the central nervous system.
Front. Cell. Neurosci. 8:257. doi: 10.3389/fncel.2014.00257
Popa-Wagner, A., Buga, A. M., Doeppner, T. R., and Hermann, D. M. (2014). Stem
cell therapies in preclinical models of stroke associated with aging. Front. Cell.
Neurosci. 8:347. doi: 10.3389/fncel.2014.00347
Roll, L., and Faissner, A. (2014). Influence of the extracellular matrix on
endogenous and transplanted stem cells after brain damage. Front. Cell.
Neurosci. 8:219. doi: 10.3389/fncel.2014.00219
Tajiri, N., Acosta, S., Portillo-Gonzales, G. S., Aguirre, D., Reyes, S., Lozano, D.,
et al. (2014). Therapeutic outcomes of transplantation of amniotic fluid-derived
stem cells in experimental ischemic stroke. Front. Cell. Neurosci. 8:227. doi:
10.3389/fncel.2014.00227
van Velthoven, C. T., Gonzalez, F., Vexler, Z. S., and Ferriero, D. M. (2014). Stem
cells for neonatal stroke- the future is here. Front. Cell. Neurosci. 8:207. doi:
10.3389/fncel.2014.00207
Xin, H., Li, Y., and Chopp, M. (2014). Exosomes/miRNAs as mediating cell-
based therapy of stroke. Front. Cell. Neurosci. 8:377. doi: 10.3389/fncel.2014.
00377
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2015 Doeppner and Hermann. This is an open-access article distributed
under the terms of the Creative Commons Attribution License (CC BY). The use,
distribution or reproduction in other forums is permitted, provided the original
author(s) or licensor are credited and that the original publication in this journal
is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
Frontiers in Cellular Neuroscience | www.frontiersin.org 3 August 2015 | Volume 9 | Article 334
